{"id":"W4206789975","doi":"10.1200/jco.2022.40.4_suppl.240","title":"Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Nivolumab; Cancer; Randomized controlled trial; FOLFOX; Oncology; Chemotherapy; Gastroesophageal Junction; Gastroenterology; Adenocarcinoma; Oxaliplatin; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001113086,0.0005233259,0.002895346,0.0003618887,0.0003620359,0.00003429569,0.0003570665,0.0002840515,0.001228782],"category_scores_gemma":[0.0004852285,0.0004345255,0.001045249,0.0005239847,0.0002178219,0.0002054535,0.0001857243,0.0009123806,0.000004433433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003300066,"about_ca_system_score_gemma":0.001886662,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001709652,"about_ca_topic_score_gemma":0.0008575436,"domain_scores_codex":[0.9949543,0.0002648368,0.002600503,0.000728064,0.0007718139,0.0006804602],"domain_scores_gemma":[0.9943315,0.001871996,0.002494745,0.0004003924,0.000319883,0.0005815225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.225542,0.002876426,0.09435271,0.0001070218,0.004933803,0.0008993447,0.0005243043,0.00487307,0.0005822416,0.00002337789,0.004595867,0.6606898],"study_design_scores_gemma":[0.2656129,0.06688382,0.5911337,0.0001304629,0.006143981,0.0002836402,0.0009513189,0.003535953,0.0009953172,0.0001389983,0.06363858,0.0005512887],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751194,0.008303443,0.0009827327,0.00973142,0.004236942,0.001257337,0.0001107296,0.00005656289,0.0002014406],"genre_scores_gemma":[0.9755421,0.01443802,0.002775254,0.001648464,0.003320582,0.0001821574,0.0001089465,0.00008099199,0.001903449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6601385,"threshold_uncertainty_score":0.9998106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1421870874614978,"score_gpt":0.4644255284061629,"score_spread":0.322238440944665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}